邻溴苄胺 | 3959-05-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 邻溴苄胺
• 中文别名: 2-溴苯甲胺；2-溴苄胺；2-溴苯甲基胺
• 英文名称: 2-bromobenzylamine
• 英文别名: (2-bromophenyl)methanamine；o-bromobenzylamine；1-(2-bromophenyl)methanamine；(2-bromophenyl)methylamine；o-bromophenylmethylamine
• CAS: 3959-05-5
• 化学式: C₇H₈BrN
• mdl: MFCD00025572
• 分子量: 186.051
• InChiKey: NOYASZMZIBFFNZ-UHFFFAOYSA-N

物化性质

• 熔点：
  36 °C
• 沸点：
  118-119°C 9mm
• 密度：
  1.481±0.06 g/cm3(Predicted)
• 闪点：
  118-119°C/9mm
• 稳定性/保质期：
  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R21/22,R34
• 海关编码：
  2921499090
• 危险品运输编号：
  UN2735
• 危险类别：
  8
• 包装等级：
  III
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  常温、避光、通风干燥处，密封保存。

SDS

Name:	2-Bromobenzylamine Material Safety Data Sheet
Synonym:	None Known
CAS:	3959-05-5

Section 1 - Chemical Product MSDS Name:2-Bromobenzylamine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3959-05-5	2-Bromobenzylamine	ca. 100	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Corrosive.
Potential Health Effects
Eye:
Causes eye burns. May cause chemical conjunctivitis and corneal damage.
Skin:
Causes skin burns. May cause skin rash (in milder cases), and cold and clammy skin with cyanosis or pale color.
Ingestion:
May cause severe and permanent damage to the digestive tract. Causes gastrointestinal tract burns. May cause perforation of the digestive tract. May cause systemic effects.
Inhalation:
Causes chemical burns to the respiratory tract. Aspiration may lead to pulmonary edema. May cause systemic effects.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed. Extensive irrigation with water is required (at least 30 minutes).
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Destroy contaminated shoes.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3959-05-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8BrN
Molecular Weight: 186.05

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3959-05-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromobenzylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 3959-05-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3959-05-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3959-05-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-溴苯甲胺是一种伯胺，属于一类重要的化工原料，广泛应用于化学工业，尤其是在精细化工和医药工业领域。

反应信息

• 作为反应物：
  描述：

  邻溴苄胺 在 叔丁基过氧化氢 、 4-phenylnaphthalene-1,2-dione 、 四丁基碘化铵 作用下， 以 水 、 乙腈 为溶剂， 反应 48.0h， 生成 2-溴苯甲酸
  参考文献：
  名称：

  通过串联邻萘醌催化和 TBHP 促进的氧化序列将伯胺一锅直接氧化成羧酸

  摘要：

  胺到羧酸的串联氧化序列是通过o -NQ 催化的胺有氧氧化成亚胺，然后是自由基引发的 TBHP 促进的亚胺中间体氧化。从机制上讲，通过 TBAI 的帮助促进了o- NQ 催化剂体系的选择性亚胺形成，这在随后 TBHP 促进的亚胺衍生物氧化以将亚胺分解为醛和胺中也很关键。反过来，释放的胺重新进入o - NQ 催化循环以产生亚胺中间体。

  DOI：

  10.1002/chem.202103450
• 作为产物：
  描述：

  2-溴溴苄 在 ammonium hydroxide 作用下， 生成 邻溴苄胺
  参考文献：
  名称：

  串联S RN 1取代后的芳基自由基的6- exo和7- end环化的实验和计算研究

  摘要：

  在亲核试剂Me 3 Sn –，Ph 2 P –和O 2 NCH 2 –的照射下，在液氨中研究了N-烯丙基-N-（2-卤代苄基）-乙酰胺和衍生物的反应。按照该程序，以高收率获得了新颖的取代的2-乙酰基-1,2,3,4-四氢异喹啉和取代的2-乙酰基-2,3,4,5-四氢-1 H-苯并[ c ]氮杂。这些反应被认为是通过芳基自由基的中间发生的，而芳基自由基的发生是通过分子内的6- exo或7- endo攻击双键环化得到脂族基团，这些脂族基团沿着S RN 1链环的传播步骤反应，得到环状取代的化合物作为主要产物。使用DFT方法对反应进行建模，该方法提供了合理的理解，可以将产物分布与作为中间体的脂肪族自由基的结构及其形成的动力学联系起来。

  DOI：

  10.1021/jo4001788
• 作为试剂：
  描述：

  7-amino-4-(methylthio)pyrido<4,3-d>pyrimidine 以 邻溴苄胺 为溶剂， 以45%的产率得到7-amino-4-(2-bromobenzylamino)pyrido[4,3-d]pyrimidine
  参考文献：
  名称：

  Bicyclic compounds capable of inhibiting tyrosine kinases of the

  摘要：

  描述了新型4-取代氨基吡啶嘧啶和4-取代氨基吡啶嘧啶抑制剂对表皮生长因子受体家族的酪氨酸激酶的作用，以及相应的药物组合物，这些药物在治疗癌症、关节炎中的滑膜侵袭、牛皮癣、血管再狭窄和血管生成方面非常有用，此外还可用于治疗胰腺炎和肾病，以及作为避孕药剂。

  公开号：

  US05654307A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• <i>N</i>-Difluoromethylthiophthalimide: A Shelf-Stable, Electrophilic Reagent for Difluoromethylthiolation
  作者：Dianhu Zhu、Yang Gu、Long Lu、Qilong Shen

  DOI：10.1021/jacs.5b03170

  日期：2015.8.26

  A new, electrophilic difluoromethylthiolating reagent N-difluoromethylthiophthalimide 3 was developed. Reagent 3 can be readily synthesized in four steps from easily available starting materials phthalimide and TMSCF2H. N-difluoromethylthiophthalimide 3 is a powerful electrophilic difluoromethylthiolating reagent that allows the difluoromethylthiolation of a wide range of nucleophiles including aryl/vinyl

  开发了一种新的亲电子二氟甲基硫代试剂 N-二氟甲基硫代邻苯二甲酰亚胺 3。试剂 3 可以很容易地从容易获得的起始材料邻苯二甲酰亚胺和 TMSCF2H 分四步合成。N-二氟甲基硫代邻苯二甲酰亚胺 3 是一种强大的亲电子二氟甲基硫醇化试剂，可对多种亲核试剂进行二氟甲基硫醇化，包括芳基/乙烯基硼酸、炔烃、胺、硫醇、β-酮酯、羟吲哚和富电子杂芳烃，如吲哚、吡咯、 1H-吡咯并[2,3-b]吡啶、咪唑并[1,2-a]吡啶、氨基噻唑、异恶唑和吡唑在温和条件下。
• NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Seong Churlmin

  公开号：US20090203708A1

  公开（公告）日：2009-08-13

  Disclosed herein are novel substituted-1H-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted-1H-quinazoline-2,4-dione derivatives are excellent in binding affinity and selectivity for 5-HT6 receptors over other receptors, inhibit serotonin(5-HT)-stimulated cAMP accumulation, and disrupt apomorphine(2 mg/kg, i.p.)-induced hyperactivity in rats. Thanks to these effects, the derivatives are useful in the treatment of 5-HT6 receptor-related central nervous system diseases.

  本文披露了一种新型的取代-1H-喹唑啉-2,4-二酮衍生物，其制备方法以及含有该衍生物的药物组合物。这种新型的取代-1H-喹唑啉-2,4-二酮衍生物在与其他受体相比对5-HT6受体的结合亲和力和选择性方面表现出色，抑制5-羟色胺（5-HT）刺激的cAMP积累，并破坏大鼠中阿波莫啡（2 mg/kg，i.p.）诱导的过度活动。由于这些效果，这些衍生物在治疗与5-HT6受体相关的中枢神经系统疾病中非常有用。
• Src kinase inhibitor compounds
  申请人：Merck & Co., Inc.

  公开号：US06498165B1

  公开（公告）日：2002-12-24

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

  嘧啶化合物（化学式I），或其药用可接受的盐、水合物、溶剂合物、晶型和单一对映异构体，以及包括这些化合物的药物组合物，它们是酪氨酸激酶酶的抑制剂，因此在预防和治疗蛋白酪氨酸激酶相关疾病方面具有用处，如免疫疾病、高增殖性疾病和其他认为不当的蛋白激酶作用可能起作用的疾病，如癌症、血管生成、动脉粥样硬化、移植排斥、类风湿性关节炎和牛皮癣。